JNK Cancer Research Results

JNK, c-Jun N-terminal kinase (JNK): Click to Expand ⟱
Source:
Type:
JNK acts synergistically with NF-κB, JAK/STAT, and other signaling molecules to exert a survival function. Janus signaling promotes cancer cell survival.
JNK, or c-Jun N-terminal kinase, is a member of the mitogen-activated protein kinase (MAPK) family. It plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis (programmed cell death). JNK is activated in response to various stress signals, such as UV radiation, oxidative stress, and inflammatory cytokines.
JNK activation can promote apoptosis in cancer cells, acting as a tumor suppressor. However, in other contexts, it can promote cell survival and proliferation, contributing to tumor progression.

JNK is often unregulated in cancers, leading to increased cancer cell proliferation, survival, and resistance to apoptosis. This activation is typically associated with poor prognosis and aggressive tumor behavior.
Scientific Papers found: Click to Expand⟱
1378- BBR,    Berberine induces non-small cell lung cancer apoptosis via the activation of the ROS/ASK1/JNK pathway
- in-vitro, Lung, NA
Apoptosis↑, Casp3↑, Cyt‑c↑, MMP↓, p‑JNK↑, eff↓,
5693- BRU,    Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2
- in-vivo, HCC, NA
NRF2↓, eff↑, p‑MAPK↑, p‑Akt↑, p‑ERK↑, p‑JNK↑,
5887- CAR,  TV,    Antitumor Effects of Carvacrol and Thymol: A Systematic Review
- Review, Var, NA
Apoptosis↑, TumCCA↑, TumMeta↓, TumCP↓, MAPK↓, PI3K↓, Akt↓, mTOR↓, eff↑, *Inflam↓, *antiOx↑, AXL↓, MDA↑, Casp3↑, Bcl-2↓, MMP2↓, MMP9↓, p‑JNK↑, BAX↑, MDA↓, TRPM7↓, MMP↓, Cyt‑c↑, Casp↑, cl‑PARP↑, ROS↑, CDK4↓, P21↑, F-actin↓, GSH↓, *SOD↑, *Catalase↑, *GPx↑, *GSR↑, *GSH↑, *lipid-P↓, *AST↓, *ALAT↓, *ALP↓, *LDH↓, DNAdam↑, AFP↓, VEGF↓, Weight↑, *chemoP↑, ROS↑,
5880- CAR,    In vitro and in vivo antitumor potential of carvacrol nanoemulsion against human lung adenocarcinoma A549 cells via mitochondrial mediated apoptosis
- vitro+vivo, Lung, A549 - in-vitro, Nor, BEAS-2B - in-vitro, Lung, PC9
Dose↝, mt-ROS↑, p‑JNK↑, BAX↑, Cyt‑c↑, Casp↑, AntiTum↑, ER Stress↑, LDH↑, selectivity↑, Apoptosis↑, DNAdam↑, IRE1↑, XBP-1↑, CHOP↓, p‑eIF2α↓, GRP78/BiP↓, Ca+2↑, MMP↓, Bcl-2↓, Casp3↑, Casp9↑, eff↓, TumW↓, Weight↑, eff↑, eff↑,
463- CUR,    Curcumin induces autophagic cell death in human thyroid cancer cells
- in-vitro, Thyroid, K1 - in-vitro, Thyroid, FTC-133 - in-vitro, Thyroid, BCPAP - in-vitro, Thyroid, 8505C
TumAuto↑, LC3II↑, Beclin-1↑, p‑p38↑, p‑JNK↑, p‑ERK↑, p62↓, p‑PDK1↓, p‑Akt↓, p‑p70S6↓, p‑PIK3R1↓, p‑S6↓, p‑4E-BP1↓,
2821- CUR,    Antioxidant curcumin induces oxidative stress to kill tumor cells (Review)
- Review, Var, NA
*antiOx↑, *NRF2↑, *ROS↓, *Inflam↓, ROS↑, p‑ERK↑, ER Stress↑, mtDam↑, Apoptosis↑, Akt↓, mTOR↓, HO-1↑, Fenton↑, GSH↓, Iron↑, p‑JNK↑, Cyt‑c↑, ATF6↑, CHOP↑,
5006- DSF,  Cu,    Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition
- vitro+vivo, lymphoma, NA
TumCD↑, TumCP↑, Apoptosis↑, NRF2↓, ROS↑, p‑JNK↑, p65↓, eff↓, NF-kB↓,
2844- FIS,    Fisetin, a dietary flavonoid induces apoptosis via modulating the MAPK and PI3K/Akt signalling pathways in human osteosarcoma (U-2 OS) cells
- in-vitro, OS, U2OS
tumCV↓, Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, BAX↑, BAD↑, Bcl-2↓, Bcl-xL↓, PI3K↓, Akt↓, ERK↓, p‑JNK↑, p‑cJun↑, p‑p38↑, ROS↑, MMP↓, mTORC1↓, PTEN↑, p‑GSK‐3β↓, GSK‐3β↑, NF-kB↓, IKKα↑, Cyt‑c↑,
1971- GamB,    Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis
- in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-435 - in-vitro, BC, MDA-MB-468 - in-vivo, NA, NA
Paraptosis↑, ER Stress↑, MMP↓, eff↓, selectivity↑, p‑ERK↑, p‑JNK↑, eff↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
486- MF,    mTOR Activation by PI3K/Akt and ERK Signaling in Short ELF-EMF Exposed Human Keratinocytes
- in-vitro, Nor, HaCaT
*mTOR↑, *PI3K↑, *Akt↑, *p‑ERK↑, *other↑, *p‑JNK↑, *p‑P70S6K↑,
218- MFrot,  MF,    Extremely low frequency magnetic fields inhibit adipogenesis of human mesenchymal stem cells
- in-vitro, Nor, NA
*PPARγ↓, *p‑JNK↑, *Wnt↑, *ALP∅, *COL1∅, *RUNX2∅, *OCN∅, *FABP4↓, *p‑JNK↑, *Diff↓,
1674- PBG,  SDT,  HPT,    Study on the effect of a triple cancer treatment of propolis, thermal cycling-hyperthermia, and low-intensity ultrasound on PANC-1 cells
- in-vitro, PC, PANC1 - in-vitro, Nor, H6c7
tumCV↓, ROS↑, eff↑, Dose∅, selectivity↑, MMP↓, mtDam↑, cl‑PARP↑, p‑ERK↓, p‑JNK↑, p‑p38↑, eff↓, ChemoSen↑,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3293- SIL,    Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer
- Review, Var, NA
hepatoP↑, TumMeta↓, Inflam↓, chemoP↑, radioP↑, Half-Life↝, *GSTs↑, p‑JNK↑, BAX↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, eff↑, TumCCA↑, STAT3↓, Mcl-1↓, survivin↓, Bcl-xL↓, Casp3↑, Casp9↑, eff↑, CXCR4↓, Dose↝,
2355- SK,    Pharmacological properties and derivatives of shikonin-A review in recent years
- Review, Var, NA
AntiCan↑, TumCP↓, TumCMig↓, Apoptosis↑, TumAuto↑, Necroptosis↑, ROS↑, TrxR1↓, PKM2↓, RIP1↓, RIP3↓, Src↓, FAK↓, PI3K↓, Akt↓, mTOR↓, GRP58↓, MMPs↓, ATF2↓, cl‑PARP↑, Casp3↑, p‑p38↑, p‑JNK↑, p‑ERK↓,
1195- SM,    Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116
T-Cell↑, TumCP∅, IL4↑, IL6↑, IFN-γ↑, TLR4↑, TLR1↑, TLR2↑, p‑JNK↑, p‑ERK↑, IKKα↑,
2279- VitK2,    Vitamin K2 Induces Mitochondria-Related Apoptosis in Human Bladder Cancer Cells via ROS and JNK/p38 MAPK Signal Pathways
- in-vitro, Bladder, T24/HTB-9 - in-vitro, Bladder, J82 - in-vitro, Nor, HEK293 - in-vitro, Nor, L02 - in-vivo, NA, NA
MMP↓, Cyt‑c↑, Casp3↑, p‑JNK↑, p‑p38↑, ROS↑, eff↓, tumCV↓, selectivity↑, *toxicity↓, TumVol↓,

Showing Research Papers: 1 to 19 of 19

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 19

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   CYP1A1↓, 1,   Fenton↑, 1,   GPx↓, 1,   GSH↓, 4,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 1,   HO-1↑, 1,   Iron↑, 1,   MDA↓, 1,   MDA↑, 1,   NQO1↓, 1,   NRF2↓, 3,   ROS↑, 9,   mt-ROS↑, 1,   SOD↓, 1,   SOD2↓, 1,   TrxR1↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   MMP↓, 7,   mtDam↑, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

LDH↑, 1,   p‑PDK1↓, 1,   p‑PIK3R1↓, 1,   PKM2↓, 1,   p‑S6↓, 1,   SIRT1↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 2,   p‑Akt↑, 1,   Apoptosis↑, 8,   ATF2↓, 1,   BAD↑, 1,   BAX↑, 6,   Bcl-2↓, 7,   Bcl-xL↓, 2,   Casp↑, 2,   Casp1↓, 1,   Casp3↑, 8,   Casp8↑, 2,   Casp9↑, 4,   Cyt‑c↑, 7,   DR5↑, 1,   Fas↑, 1,   FasL↑, 1,   GRP58↓, 1,   HGF/c-Met↓, 1,   p‑JNK↑, 17,   MAPK↓, 2,   p‑MAPK↑, 1,   Mcl-1↓, 1,   p‑MDM2↓, 1,   Necroptosis↑, 1,   p‑p38↓, 1,   p‑p38↑, 8,   Paraptosis↑, 1,   RIP1↓, 1,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics ⓘ

p‑cJun↑, 1,   H3↓, 1,   H4↓, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↓, 1,   CHOP↑, 2,   p‑eIF2α↓, 1,   p‑eIF2α↑, 1,   ER Stress↑, 3,   GRP78/BiP↓, 1,   IRE1↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   LC3II↑, 2,   p62↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

DNAdam↑, 2,   PARP↑, 1,   cl‑PARP↑, 6,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK4↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

p‑4E-BP1↓, 1,   CD34↓, 1,   cFos↑, 1,   EMT↓, 1,   ERK↓, 1,   p‑ERK↓, 5,   p‑ERK↑, 5,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   mTOR↓, 4,   mTORC1↓, 1,   NOTCH1↓, 1,   PI3K↓, 3,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 1,   Src↓, 1,   p‑Src↓, 1,   STAT3↓, 2,   p‑STAT6↓, 1,   TRPM7↓, 1,  

Migration ⓘ

AXL↓, 2,   Ca+2↑, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 1,   F-actin↓, 1,   FAK↓, 2,   ITGB1↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 2,   MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   Rac1↓, 1,   Rho↓, 1,   RIP3↓, 1,   Snail↓, 1,   TumCMig↓, 1,   TumCP↓, 3,   TumCP↑, 1,   TumCP∅, 1,   TumMeta↓, 2,   Tyro3↓, 1,   Vim↑, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↑, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IKKα↑, 2,   IL2↑, 1,   IL4↑, 1,   IL6↓, 1,   IL6↑, 1,   Inflam↓, 2,   NF-kB↓, 3,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   T-Cell↑, 1,   TLR1↑, 1,   TLR2↑, 1,   TLR4↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 2,   Dose↝, 3,   Dose∅, 1,   eff↓, 7,   eff↑, 7,   Half-Life↝, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

AFP↓, 1,   AR↓, 1,   CEA↓, 1,   EGFR↑, 1,   IL6↓, 1,   IL6↑, 1,   LDH↑, 1,   NSE↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   AntiTum↑, 1,   cachexia↓, 1,   chemoP↑, 2,   hepatoP↑, 1,   radioP↑, 1,   TumVol↓, 3,   TumW↓, 1,   Weight↑, 2,  
Total Targets: 187

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 2,   lipid-P↓, 2,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 2,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   FABP4↓, 1,   LDH↓, 1,   PPARγ↓, 1,  

Cell Death ⓘ

Akt↑, 1,   Casp3↓, 1,   p‑JNK↑, 3,  

Kinase & Signal Transduction ⓘ

OCN∅, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

Diff↓, 1,   p‑ERK↑, 1,   mTOR↑, 1,   p‑P70S6K↑, 1,   PI3K↑, 1,   RUNX2∅, 1,   Wnt↑, 1,  

Migration ⓘ

COL1∅, 1,  

Immune & Inflammatory Signaling ⓘ

IL10↑, 1,   IL1β↓, 1,   Inflam↓, 2,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   ALP∅, 1,   AST↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   hepatoP↑, 1,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 42

Scientific Paper Hit Count for: JNK, c-Jun N-terminal kinase (JNK)
3 Silymarin (Milk Thistle) silibinin
2 Carvacrol
2 Curcumin
2 Magnetic Fields
1 Berberine
1 brusatol
1 Thymol-Thymus vulgaris
1 Disulfiram
1 Copper and Cu NanoParticles
1 Fisetin
1 Gambogic Acid
1 Luteolin
1 Magnetic Field Rotating
1 Propolis -bee glue
1 SonoDynamic Therapy UltraSound
1 Hyperthermia
1 Shikonin
1 Salvia miltiorrhiza
1 Vitamin K2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:168  State#:1  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page